GMAB vs NVS
Genmab A/S vs Novartis AG — AI-powered side-by-side comparison
| Metric | GMAB | NVS |
|---|
| AI Score |
60
|
75
|
| Price |
$30.82
|
$154.64
|
| P/E Ratio |
24.04×
|
23.55×
|
| ROE |
16.5%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
39.9%
|
74.3%
|
| Debt / Equity |
0.89×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
72.5
|
57.7
|
| Beta |
0.685
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for GMAB versus NVS.
NVS leads by 15 points.
NVS scores 75/100 (Buy) versus GMAB at 60/100 (Buy).
GMAB Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- EPS declining -25.3% YoY despite any revenue growth — Growth
- RSI at 73 is in overbought territory — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical